The medical community is excited with anticipation surrounding retatrutide, a new dual GIP and GLP-1 target that’s exhibiting significant potential in clinical trials for treating obesity. Unlike some existing weight loss approaches, retatrutide appears to provide a more substantial loss in body weight and enhance metabolic markers, particularly